BioCryst to Report Second Quarter 2021 Financial Results on August 5
BioCryst Pharmaceuticals (BCRX) will report its Q2 2021 financial results on August 5, 2021. The conference call at 8:30 a.m. ET will provide insights into the company's performance and future outlook. BioCryst is known for its development of oral medicines for rare diseases, including ORLADEYO for HAE prevention. The company also has ongoing projects like BCX9930 for complement-mediated diseases and galidesivir for Marburg virus treatment, showcasing a strong commitment to addressing significant medical needs.
- Approval of ORLADEYO for HAE treatments highlights product pipeline strength.
- Ongoing development programs, including BCX9930 and galidesivir, signify growth potential.
- None.
RESEARCH TRIANGLE PARK, N.C., July 22, 2021 (GLOBE NEWSWIRE) -- BioCryst Pharmaceuticals, Inc. (Nasdaq: BCRX) today announced that the company will report its second quarter 2021 financial results on Thursday, August 5, 2021.
BioCryst management will host a conference call and webcast at 8:30 a.m. ET that day to discuss the financial results and provide a corporate update.
The live call may be accessed by dialing 877-303-8027 for domestic callers and 760-536-5165 for international callers and using conference ID # 9886913. A live webcast of the call and any slides will be available online at the investors section of the company website at www.biocryst.com. A telephone replay of the call will be available by dialing 855-859-2056 for domestic callers or 404-537-3406 for international callers and entering the conference ID # 9886913.
About BioCryst Pharmaceuticals
BioCryst Pharmaceuticals discovers novel, oral, small-molecule medicines that treat rare diseases in which significant unmet medical needs exist and an enzyme plays a key role in the biological pathway of the disease. Oral, once-daily ORLADEYO® (berotralstat) is approved in the United States, the European Union, Japan and the United Kingdom for the prevention of HAE attacks in adults and pediatric patients 12 years and older. BioCryst has several ongoing development programs including BCX9930, an oral Factor D inhibitor for the treatment of complement-mediated diseases, BCX9250, an ALK-2 inhibitor for the treatment of fibrodysplasia ossificans progressiva, and galidesivir, a potential treatment for Marburg virus disease and Yellow Fever. RAPIVAB® (peramivir injection), a viral neuraminidase inhibitor for the treatment of influenza, has received regulatory approval in the U.S., Canada, Australia, Japan, Taiwan and Korea. Post-marketing commitments for RAPIVAB are ongoing. For more information, please visit the company’s website at www.biocryst.com.
BCRXW
Contact:
Investors
John Bluth
+1 919 859 7910
jbluth@biocryst.com
Media
Catherine Collier Kyroulis
+1 917 886 5586
ckyroulis@biocryst.com
FAQ
When will BioCryst Pharmaceuticals report its Q2 2021 earnings?
What time is the BioCryst Pharmaceuticals conference call?
What are the key products of BioCryst Pharmaceuticals?